Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,112 questions in 171 reviews · Eyes and Vision
current versionsNo studies 587 · 27.8%Ungraded 95 · 4.5%Very low 446 · 21.1%Low 557 · 26.4%Moderate 361 · 17.1%High 66 · 3.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Antiviral (B) versus debridement (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14… Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis (2015) · Cochrane | no estimate extracted | 7 participants | Low |
Intervention NR Debridement + antiviral or interferon (B) versus debridement (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14… Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis (2015) · Cochrane | no estimate extracted | 7 participants | Moderate |
Intervention NR Debridement + antiviral (B) versus antiviral (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14… Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis (2015) · Cochrane | no estimate extracted | 7 participants | Moderate |
Intervention NR Vidarabine (B) versus inactive control (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14… Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis (2015) · Cochrane | no estimate extracted | 7 participants | Low |
Intervention NR Vidarabine (B) versus idoxuridine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14… Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis (2015) · Cochrane | no estimate extracted | 7 participants | Moderate |
Intervention NR Trifluridine (B) versus idoxuridine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14… Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis (2015) · Cochrane | no estimate extracted | 7 participants | Moderate |
Intervention NR Acyclovir (B) versus idoxuridine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14… Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis (2015) · Cochrane | no estimate extracted | 7 participants | Moderate |
Intervention NR Brivudine (B) versus idoxuridine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14… Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis (2015) · Cochrane | no estimate extracted | 7 participants | Moderate |
Intervention NR Trifluridine (B) versus vidarabine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14… Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis (2015) · Cochrane | no estimate extracted | 7 participants | Moderate |
Intervention NR Acyclovir (B) versus vidarabine (A) · trial participants with dendritic or geographic epithelial keratitis Outcomes: corneal epithelial healing at 7 and 14… Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis (2015) · Cochrane | no estimate extracted | 7 participants | Moderate |
Intervention NR Clnical cure at 2 to 3 months · people with fungal ulcers Medical interventions for fungal keratitis (2015) · Cochrane | RR 1.07 [0.89, 1.28] | 1 study · 30 participants | Low |
Intervention NR Best corrected visual acuity at 2 to 3 months (measured using logMAR scale. A score of 0 = good vision, higher score is worse vision) · people with fungal ulcers Medical interventions for fungal keratitis (2015) · Cochrane | no estimate extracted | 3 studies · 434 participants | Low |
Intervention NR Time to clinical cure · people with fungal ulcers Medical interventions for fungal keratitis (2015) · Cochrane | hazard ratio 1.25 [0.88, 1.15] | 2011 participants | High |
Intervention NR Compliance with treatment · people with fungal ulcers Medical interventions for fungal keratitis (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Corneal perforation or penetrating keratoplasty, or both, at 2 to 3 months · people with fungal ulcers Medical interventions for fungal keratitis (2015) · Cochrane | RR 0.61 [0.4, 0.94] | 3 studies · 434 participants | High |
Intervention NR Quality of life · people with fungal ulcers Medical interventions for fungal keratitis (2015) · Cochrane | no estimate extracted | NR | No studies |
MMC vs 5‐FU Failure of functioning trabeculectomy at 1 year · wound healing in glaucoma surgery Mitomycin C versus 5‐Fluorouracil for wound healing in glaucoma surgery (2015) · Cochrane | RR 0.65 [0.19, 2.2] | 11 studies · 634 participants | Low |
MMC vs 5‐FU Intraocular pressure at 1 year · wound healing in glaucoma surgery Mitomycin C versus 5‐Fluorouracil for wound healing in glaucoma surgery (2015) · Cochrane | no estimate extracted | 7 studies · 386 participants | Low |
MMC vs 5‐FU Loss of 2 or more lines of Snellen visual acuity at 1 year · wound healing in glaucoma surgery Mitomycin C versus 5‐Fluorouracil for wound healing in glaucoma surgery (2015) · Cochrane | RR 2 [0.53, 7.59] | 5 studies · 328 participants | Low |
MMC vs 5‐FU Postoperative complications: late hypotony · wound healing in glaucoma surgery Mitomycin C versus 5‐Fluorouracil for wound healing in glaucoma surgery (2015) · Cochrane | RR 1.37 [0.41, 4.63] | 4 studies · 211 participants | Low |
MMC vs 5‐FU Postoperative complications: choroidal detachment · wound healing in glaucoma surgery Mitomycin C versus 5‐Fluorouracil for wound healing in glaucoma surgery (2015) · Cochrane | RR 0.86 [0.45, 1.63] | 8 studies · 494 participants | Low |
MMC vs 5‐FU Postoperative complications: endophthalmitis · wound healing in glaucoma surgery Mitomycin C versus 5‐Fluorouracil for wound healing in glaucoma surgery (2015) · Cochrane | RR 3.89 [0.44, 34.57] | 4 studies · 315 participants | Low |
MMC vs 5‐FU Quality of life at 1 year · wound healing in glaucoma surgery Mitomycin C versus 5‐Fluorouracil for wound healing in glaucoma surgery (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table: photocoagulation of drusen vs control Outcomes at two years Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration (2015) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings table: photocoagulation of drusen vs control Development of CNV Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration (2015) · Cochrane | OR 1.07 [0.79, 1.46] | 11 studies · 2159 participants | High |
Summary of findings table: photocoagulation of drusen vs control Development of geographic atrophy Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration (2015) · Cochrane | OR 1.3 [0.38, 4.51] | 2 studies · 148 participants | Low |
Summary of findings table: photocoagulation of drusen vs control Visual loss of 2‐3+ lines of visual acuity Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration (2015) · Cochrane | OR 0.99 [0.81, 1.22] | 9 studies · 2002 participants | Moderate |
Summary of findings table: photocoagulation of drusen vs control Loss of ≥ 0.3 log units of contrast sensitivity Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration (2015) · Cochrane | OR 0.82 [0.2, 3.31] | 1 study · 82 participants | Low |
Summary of findings table: photocoagulation of drusen vs control Reading speed in words/minute Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration (2015) · Cochrane | no estimate extracted | 1 study · 44 participants | Low |
Summary of findings table: photocoagulation of drusen vs control Drusen reduction Laser treatment of drusen to prevent progression to advanced age‐related macular degeneration (2015) · Cochrane | OR 9.16 [6.28, 13.4] | 3 studies · 570 participants | High |
Combined surgery vs phacoemulsification alone Mean change in IOP Measured by Goldmann applanation · patients with eyes with cataract and glaucoma Combined surgery versus cataract surgery alone for eyes with cataract and glaucoma (2015) · Cochrane | no estimate extracted | 6 studies · 489 participants | Low |
Combined surgery vs phacoemulsification alone Mean change in medications Measured by number of bottles · patients with eyes with cataract and glaucoma Combined surgery versus cataract surgery alone for eyes with cataract and glaucoma (2015) · Cochrane | no estimate extracted | 2 studies · 301 participants | Low |
Combined surgery vs phacoemulsification alone Proportion using one or more medications at one year after surgery Number of participants · patients with eyes with cataract and glaucoma Combined surgery versus cataract surgery alone for eyes with cataract and glaucoma (2015) · Cochrane | RR 0.47 [0.28, 0.8] | 5 studies · 453 participants | Low |
Combined surgery vs phacoemulsification alone Proportion who received re‐operation to control IOP within one year Number of participants · patients with eyes with cataract and glaucoma Combined surgery versus cataract surgery alone for eyes with cataract and glaucoma (2015) · Cochrane | RR 1.13 [0.15, 8.25] | 4 studies · 382 participants | Low |
Combined surgery vs phacoemulsification alone Proportion who received intervention for surgical complications within one year Number of participants · patients with eyes with cataract and glaucoma Combined surgery versus cataract surgery alone for eyes with cataract and glaucoma (2015) · Cochrane | RR 1.06 [0.34, 3.35] | 4 studies · 382 participants | Low |
Vitrectomy vs observation Mean visual acuity (logMAR) at 6‐12 months · participants with idiopathic macular hole Vitrectomy for idiopathic macular hole (2015) · Cochrane | no estimate extracted | 3 studies · 270 participants | Moderate |
Vitrectomy vs observation Hole closure at 6‐12 months · participants with idiopathic macular hole Vitrectomy for idiopathic macular hole (2015) · Cochrane | OR 31.4 [14.9, 66.3] | 3 studies · 265 participants | High |
Vitrectomy vs observation Reading acuity at 6 months · participants with idiopathic macular hole Vitrectomy for idiopathic macular hole (2015) · Cochrane | no estimate extracted | 2 studies · 154 participants | Low |
Vitrectomy vs observation Reading speed (word/minute) at 6 months · participants with idiopathic macular hole Vitrectomy for idiopathic macular hole (2015) · Cochrane | no estimate extracted | 1 study · 118 participants | Low |
Vitrectomy vs observation Hole recurrence · participants with idiopathic macular hole Vitrectomy for idiopathic macular hole (2015) · Cochrane | no estimate extracted | NR | No studies |
Vitrectomy vs observation Adverse outcomes · participants with idiopathic macular hole Vitrectomy for idiopathic macular hole (2015) · Cochrane | no estimate extracted | 1997 participants | Ungraded |
Vitrectomy vs observation Costs · participants with idiopathic macular hole Vitrectomy for idiopathic macular hole (2015) · Cochrane | no estimate extracted | NR | No studies |
Omega 3 fatty acids vs placebo Loss of 3 or more lines of VA at 24 months · people with AMD Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration (2015) · Cochrane | RR 1.14 | 1 study · 236 participants | Moderate |
Omega 3 fatty acids vs placebo Loss of 3 or more lines of VA at 36 months · people with AMD Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration (2015) · Cochrane | RR 1.25 | 1 study · 230 participants | Moderate |
Omega 3 fatty acids vs placebo Incidence of CNV at 24 months · people with AMD Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration (2015) · Cochrane | RR 1.06 | 1 study · 224 participants | Moderate |
Omega 3 fatty acids vs placebo Incidence of CNV at 36 months · people with AMD Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration (2015) · Cochrane | RR 1.12 | 1 study · 195 participants | Moderate |
Omega 3 fatty acids vs placebo Progression of AMD over 5 years · people with AMD Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration (2015) · Cochrane | HR 0.96 [0.84, 1.1] | 2 studies · 2343 participants | High |
Omega 3 fatty acids vs placebo Adverse effects · people with AMD Omega 3 fatty acids for preventing or slowing the progression of age‐related macular degeneration (2015) · Cochrane | RR 1.01 | 2 studies · 2343 participants | High |
Intervention NR Progression (increase in maximal keratometry of 1.5 dioptres or more) · people with keratoconus Corneal collagen cross‐linking for treating keratoconus (2015) · Cochrane | RR 0.12 [0.01, 2] | 1 study · 19 participants | Very low |
Intervention NR Steepness of the cornea (maximal keratometry) (measured using dioptres. A higher dioptre represents steeper cornea and worse outcome) · people with keratoconus Corneal collagen cross‐linking for treating keratoconus (2015) · Cochrane | no estimate extracted | 1 study · 94 participants | Very low |